A Randomized Controlled Trial of colistin combined with sulbactam : 9 g/day versus 12 g/day in treatment of multi-drugs resistance Acinetobacter baumannii (MDR Acinetobacter baumannii) pneumonia

Phase 4

Recruiting

• Conditions: Multidrug resistance Acinetobacter baumannii pneumonia; MDR A. baumannii; Colistin; High dose sulbactam

• Registration Number: TCTR20210227001
• Lead Sponsor: Department of Medicine, Phramongkutklao Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-02-26
• Study Start: 2021-02-27
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

1. A. baumannii MDR pneumonia patients
2. Age 18 or over 18 years old

Exclusion Criteria

1. Sputum culture shows mixed organisms
2. Concurrent or coinfection with other organs
3. Not received colistin for empirical treatment
4. Receive colistin >6 calendar days before date of collected sputum
5. Allergy to colistin or sulbactam
6. Previous participated in this trial within 14 days
7. Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mortality 7 and 28 days mortality rate

Secondary Outcome Measures

Name	Time	Method
ICU day, ventilator day, adverse even until discharge from ICU, off mechanical ventilator, complete treatment length of ICU stay or mechanical ventilator use, adverse drug events